Francisco Salva

Mr. Salva has a proven dedication to building companies, including over a decade in biopharmaceutical executive leadership and a decade in life science venture capital and investment banking. His growth-oriented experience transcends numerous business functions, including corporate finance, business development, portfolio management and clinical operations. Prior to Complexa, Mr. Salva was a Founder and Vice President of Operations at Acerta Pharma, which successfully developed acalabrutinib, a second generation Bruton’s tyrosine kinase inhibitor, prior to being acquired by AstraZeneca for $4 billion to date (expected total consideration of over $6 billion). Before Acerta Pharma, Mr. Salva served as Senior Director of Corporate Development at Pharmacyclics, where he participated in the strategic turnaround of the company that reprioritized focus and efforts on ibrutinib, a key driver of AbbVie’s $21 billion acquisition of the company. Mr. Salva holds dual Bachelor of Arts degrees in Business Economics and Philosophy from Brown University and a Master of Science degree in Economics (Economics and Philosophy specialty) from the London School of Economics and Political Science.